Chardan Capital Markets has recently initiated Mind Medicine (MindMed) Inc (MNMD) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on October 14, 2024, Leerink ...

Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...

Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $2.23 which represents a slight increase of $0.04 or 1.83% from the prior close of $2.19. The stock opened at $2.19 and ...

Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research report issued on Friday,Benzinga reports. They presently ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy ...

Eyenovia said it hired Chardan as its financial adviser as it goes through a business review that includes a potential sale of the company.

Eyenovia, Inc., an ophthalmic technology company, has announced it is consulting with Chardan as its financial advisor to explore various strategic alternatives, including potential business ...

Eyenovia (EYEN) has engaged Chardan as its financial advisor in connection with its evaluation of strategic alternatives. With assistance from ...

With assistance from Chardan, the Company will continue to assess a full range of strategic alternatives, including but not limited to, a business combination, sale of the Company, reverse merger, ...

(MENAFN- GlobeNewsWire - Nasdaq) Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% Along with the ...

With assistance from Chardan, the Company will continue to assess a full range of strategic alternatives, including but not limited to, a business combination, sale of the Company, reverse merger ...